Podcasts about De novo

A Série A entrou no debate no 45 Minutos com uma tierlist completa dos times do Brasileirão. Onde o Bahia realmente se encaixa? O Vitória corre riscos em 2026? E, mais uma vez, o Mirassol virou motivo de dúvida na mesa.Fred Figueiroa, Cassio Zirpoli e Ravel Pinheiro analisam forças, elencos, contextos e projeções para a […]

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Edgard Maciel de Sá, Phill e Jéssica Maldonado analisam a vitória no Fla-Flu, a evolução de Santi Moreno, o planejamento para o Brasileiro e a estreia contra o Grêmio. Dá o play!

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

JHLT: The Podcast returns with an episode discussing the paper, "Impact of evolocumab on coronary physiology and microstructure in de-novo heart transplant recipients," from the January issue of JHLT. Featured on this episode is early career guest host Bin Yang, MD, of Massachusetts General Hospital. Mentored by Digital Media Editor Van-Khue Ton, MD, PhD, Dr. Yang shares hosting duties this episode and brings great questions to the discussion. Drs. Yang and Ton are joined by the first author, Salma Karim, and senior author, Hans Eiskjaer, both from Aarhus University Hospital in Denmark. The discussion explores: What imaging and physical markers the researchers used to determine if evolocumab was influencing the development of cardiac allograft vasculopathy (CAV) The potential role of lipid-lowering therapies or statins in treating CAV The relationship between CAV and microvascular resistance (IMR) For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. In case you missed it, earlier this month the JHLT Digital Media Editors recapped their favorite papers from 2025. Take a listen! Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

O ministro Dias Toffoli, do STF, encurtou de seis para dois dias o período para que os investigadores da Polícia Federal colham os depoimentos dos investigados.Toffoli também prorrogou por mais 60 dias as investigações sobre a operação de venda do Banco Master pelo Banco de Brasília, após pedido da PF. Duda Teixeira e Magno Karl comentam:O ministro Dias Toffoli, do STF, encurtou de seis para dois dias o período para que os investigadores da Polícia Federal colham os depoimentos dos investigados.Toffoli também prorrogou por mais 60 dias as investigações sobre a operação de venda do Banco Master pelo Banco de Brasília, após pedido da PF. Duda Teixeira e Magno Karl comentam:O ministro Dias Toffoli, do STF, encurtou de seis para dois dias o período para que os investigadores da Polícia Federal colham os depoimentos dos investigados.Toffoli também prorrogou por mais 60 dias as investigações sobre a operação de venda do Banco Master pelo Banco de Brasília, após pedido da PF. Duda Teixeira e Magno Karl comentam:

Galo esbarra em primeiro tempo ruim e falta de pontaria para só empatar com o North. 2 pontos em 6 possíveis escancara carências do elenco ou é cedo para ligar alerta? Com Henrique Fernandes, André Ribas, Carol Leandro e Laura Rezende.

Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo Vigilante: 10% de desconto para audiência do Meio-Dia em Brasília   https://bit.ly/meiodiaoa   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Porque a vida é assim, um mosaico de momentos que só faz sentido quando olhamos o conjunto. Olhar pra trás, por outro lado, é um passo essencial para qualquer virada verdadeira. É como se cada conquista fosse um lembrete silencioso dizendo, vai, continua, você consegue ir além.Bem-vindo ao episódio especial de Ano-Novo número 104 de Domingo à Noite. Vamos começar a semana botando o tédio pra fora.Ouça o episódio nas principais plataformas de podcast, para ouvir e conferir os links nas mídias sociais acesse: https://linktr.ee/kazzttorpodcastSiga André Arruda, o apresentador e faz tudo nesse podcast nas mídias sociais. Acesse os perfis em: https://linktr.ee/kazzttorPodcast produzido por Kazzttor AMT: https://www.kazzttor.com.brFeliz, Ano-Novo! Feliz 2026!

Siga nosso novo canal INDO PRAS IDEIAS: https://www.youtube.com/@indoprasideiasSiga nosso canal de CORTES: https://www.youtube.com/@IconografiadaHistoria-cortesAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Eduardo GoesDireção: Fernando Zeneratto / Joel Paviotti

A KTO é o melhor lugar para você fazer sua aposta. KTO.bet.br - apenas para maiores de 18 anos. Jogue com responsabilidade. kto.bet.br/cafebelgradoTodos os links do Belgradão: https://linktr.ee/ocafebelgradoAssine o conteúdo exclusivo do Café Belgrado em www.cafebelgrado.com.br e tenha acesso a uma variedade de séries exclusivas que vão te encantar:Aproveite o cupom: cafebelgrado em www.pholias.com.br e tenha 20% de desconto! É oferta por tempo limitado!!Amanhã Vai Ser Outro Dia, O Reinado, The Next Dance: A História de Luka Doncic, Belgramadness, El Gringo, BelgraVerso, MIP Hunters, Esquema de Pirâmide, F.A.D.I.N.H.A., Wemby Watch e muitos outros conteúdos empolgantes que estão esperando por você!

Na estorinha do dia 26 de dezembro, Glaydson Botelho conta a estória "Receita de novo ano" Acesse aqui o conteúdo completo!

Hoje Lucas e Marcelo (com o microfone desligadíssimo) fazem mais um especial episódio de Natal!!⁠⁠⁠⁠⁠⁠⁠Edição: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Daniel Bayer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Arte da Capa: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Daltrinador

Siga nosso canal de CORTES: https://www.youtube.com/@IconografiadaHistoria-cortesAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Fernando ZenerattoRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Fernando ZenerattoDireção: Fernando Zeneratto

Siga nosso canal de CORTES: https://www.youtube.com/@IconografiadaHistoria-cortesAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Eduardo GoesDireção: Fernando Zeneratto / Joel Paviotti

Siga nosso canal de CORTES: https://www.youtube.com/@IconografiadaHistoria-cortesAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Eduardo GoesDireção: Fernando Zeneratto / Joel Paviotti

Neste episódio, Paulo, Thiago, Rafael, Chuvisco e Arthur leem emails ficados para trás e ouvem o relato de como o Dr. Sub Zero atacou novamente mais um membro do Godmode. Todos os links do godmode agora estão organizados aqui - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/godmode.podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Se for mandar email reclamando - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠contato@godmodepodcast.com⁠⁠⁠

Fred Gomes recebe Manu Ribeiro, Thiago Lima e Pedro Henrique Cardoso para debater vitória por 2 a 0.

durée : 00:45:58 - On n'arrête pas l'éco - par : Alexandra Bensaid - Au menu ce samedi : un débat sur le projet d'euro numérique, un détour par Madrid, un reportage sur le commerce illicite de médicaments contrefaits... Et un entretien avec le patron France de Novo Nordisk, dont les traitements Ozempic ou Wegovy affinent les silhouettes et transforment l'économie. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

"Jesus respondeu, e disse-lhe: Na verdade, na verdade te digo que aquele que não nascer de novo, não pode Ver o Reino de Deus." João 3:3"Jesus respondeu: Na verdade, na verdade te digo que aquele que não nascer da água e do Espírito, não pode Entrar no Reino de Deus." João 3:5

Justiça volta a deixar a assessoria esportiva The Run fora do Parque do Ibirapuera; saiu o sorteio da Maratona do Rio; ajude uma pesquisa da USPParticipe da pesquisa da USPFormulário - https://forms.gle/irpfKhntx8MKnZ6K6Entre em contato com o responsável (Vithor): 11 97997 6295Assine a nossa newsletter e fique sempre bem informado - https://corridanoar.com/newsletterLinks citados nos vídeos - https://linktr.ee/corridanoarO Corrida no Ar News é produzido diariamente e postado por volta das 6 da manhã.

Polícia prende suspeito de roubo de obras de arte na Biblioteca Mário de Andrade. E filme 'O Agente Secreto' recebe três indicações ao Globo de Ouro. See omnystudio.com/listener for privacy information.

O Bate-Pronto de hoje projetará a estreia do Flamengo na Copa Intercontinental contra o Cruz Azul. O jogo será amanhã. O time rubro-negro tem condições de sonhar com o título contra o PSG? O programa também debaterá a nova troca de farpas entre Leila Pereira e Bap e atualizará as principais informações do futebol mundial.

Lamba lambda lambda, nerds! Com a Mega da Virada prestes a pagar um prêmio de UM BILHÃO DE REAIS, resolvemos voltar ao NerdCast mais clássico de todos os tempos (segundo vocês), para mais um papo com juros e correção monetária sobre nossas maiores excentricidades da vida de bilionário. Neste programa, Alottoni, Pedro Duarte, Sr. K, Didi Braguinha, Tucano e Azaghal debatem se com R$ 200 mil por mês AINDA dá pra se viver com tranquilidade, se o Concorde é o novo Antonov, e mais delírios extravagantes no sonho do bilhão próprio. Estoure a champanhe e não se arrependa de nada com nossos especialistas da deseducação financeira! Leapmotor Assista à NerdTour de São Lourenço com Leapmotor: https://jovemnerd.short.gy/Leapmotor_NerdTour_NerdCast Ozob: A Cyberpunk Board Game NOVA CHANCE para apoiar a campanha até 09/12! Mais informações em: https://ozob.com.br/ Magalu Cloud Saiba mais sobre a edição 2025 do evento Cloud Futures: https://jovemnerd.short.gy/Maglu_cloud_SPOT_NERDCAST Fanlab Conheça Fanlab, roupas e acessórios de moda geek: https://jovemnerd.short.gy/FanLab_D5_SPOT_ccxp CITADO NO PROGRAMA:Airbnb do Sr. M - Ficou com vontade de conhecer São Lourenço? Hospede-se no apartamento do Sr. M! O mesmo que a Portuguesa morou. Localização privilegiada! Reserve sua estadia: https://airbnb.com/h/jl408Como Vovó Fazia - Financiamento coletivo do Pedro Duarte: https://www.catarse.me/comovovofaziaCONFIRA OS OUTROS CANAIS DO JOVEM NERD E-MAILS Mande suas críticas, elogios, sugestões e caneladas para nerdcast@jovemnerd.com.br APP JOVEM NERD: Google Play Store | Apple App Store ARTE DA VITRINE: Randall Random Baixe a versão Wallpaper da vitrine EDIÇÃO COMPLETA POR RADIOFOBIA PODCAST E MULTIMÍDIA Learn more about your ad choices. Visit megaphone.fm/adchoices

Este boletim traz um resumo das principais notícias do dia na análise de Samuel Possebon, editor chefe da TELETIME.TELETIME é a publicação de referência para quem acompanha o mercado de telecomunicações, tecnologia e Internet no Brasil. Uma publicação independente dedicada ao debate aprofundado e criterioso das questões econômicas, regulatórias, tecnológicas, operacionais e estratégicas das empresas do setor. Se você ainda não acompanha a newsletter TELETIME, inscreva-se aqui (shorturl.at/juzF1) e fique ligado no dia a dia do mercado de telecom. É simples e é gratuito.Você ainda pode acompanhar TELETIME nas redes sociais:Linkedin: https://www.linkedin.com/company/teletimenews/Facebook: https://www.facebook.com/Teletime/ Ou entre em nosso canal no Telegram: https://t.me/teletimenews Hosted on Acast. See acast.com/privacy for more information.

"Jesus respondeu: Na verdade, na verdade te digo que aquele que não nascer da água e do Espírito, não pode Entrar no Reino de Deus.O que é nascido da carne é carne, e o que é nascido do Espírito é espírito." João 3:5-6"O fariseu, estando em pé, orava consigo desta maneira: Ó Deus, graças Te dou porque não sou como os demais homens, roubadores, injustos e adúlteros; nem ainda como este publicano.Jejuo duas vezes na semana, e dou os dízimos de tudo quanto possuo.O publicano, porém, estando em pé, de longe, nem ainda queria levantar os olhos ao Céu, mas batia no peito, dizendo: Ó Deus, tem misericórdia de mim, pecador!Digo-vos que este desceu justificado para sua casa, e não aquele; porque qualquer que a si mesmo se exalta será humilhado, e qualquer que a si mesmo se humilha será exaltado." Lucas 18:11-14

Quando as dificuldades vêm, podemos enfrentá-las de frente. Hoje Joyce compartilha encorajamento para ajudá-lo a derrotar seus gigantes.

VARzea #356

Episode Intro:One of the two runners up for the Wilkes Center Climate Launch Prize this past year is De Novo Foodlabs, a startup with operations in North Carolina and Cape Town, South Africa, which is focused on using precision fermentation to synthesize a new kind of lactoferrin.  I had to read up on this myself, but Lactoferrin, is a nutrient found exclusively in milk from mammals. It's in human breast milk, but commonly it's harvest from cow's milk and sold as an ingredient for infant formula, nutritional supplements, and health drinks. Lactoferrin is not only very important for infant health, but increasingly it's seen as a valuable nutritional additive for adults.  BUT, and here's where the environmental/climate impacts come in – producing lactoferrin requires A LOT of cow milk currently.  And raising cows for their milk, comes with a heavy toll on land and water resources, not to mention methane emissions from cattle.  Enter, the potential for precision fermentation – which is basically laboratory grown lactoferrin – and companies like De Novo Foodlabs, which is hoping to capitalize on this growing demand for this health product, and help to save the climate while they're at it.  Jean Louwrens, is one of the co-founders of De Novo Foodlabs, and he recently made some time to chat with me about their work, and the opportunities he sees for precision fermentation as a climate-friendly solution.  Interview Summary:Jean Louwrens of De Novo Foodlabs discusses how his company uses precision fermentation and bioinformatic AI to produce NanoFerrin™, a sustainable, affordable alternative to bovine lactoferrin. Lactoferrin, vital for infant immunity, iron absorption, and overall health, is currently scarce and costly due to reliance on cow's milk. De Novo aims to expand supply, reduce costs, and enable broader use in infant formula, supplements, and functional foods. He highlights market growth, competition, regulatory challenges, and the environmental benefits of reducing reliance on dairy farming, while also developing synergistic brain and gut health ingredients for longevity nutrition.Episode webpage:wilkescenter.utah.edu/podcast/32-lab-generated-lactoferrin-better-for-planet/

Con Javier Cabrera, de XTB.

Economia americana passa por fim do shutdown e das tarifas de importação a alguns países

Claudio Portella, Sergio Santana, Maria Clara Modesto e Pedro Dep repercutem a vitória por 3 a 2 do Botafogo contra o Grêmio, no Nilton Santos, que assegurou a terceira participação seguida do clube na Libertadores. Muita informação e opinião! Dá o play!

A saúde e o bem-estar das comunidades multiculturais mais jovens na Austrália. Como construir espaços mais inclusivos, saudáveis para quem está começando uma nova vida por aqui? Conversamos com Ranielson Santana, presidente da BASA (Associação Brasileira da Austrália do Sul), Patrícia Alves de Araújo, coordenadora do Projeto Multicultural no Northern Grampians Shire Council e Junior Melo, do Centro Esportivo para Jovens Multiculturais (CMSport).

Siga nosso canal de CORTES: https://www.youtube.com/@IconografiadaHistoria-cortesAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Eduardo GoesDireção: Fernando Zeneratto / Joel Paviotti

Jurandir Filho, Felipe Mesquita, Evandro de Freitas e Bruno Carvalho batem um papo sobre diversos assuntos, afinal, esse é mais um Happy Hour, nosso podcast com conversas sobre vários tópicos e temas! Simplesmente bateram DE NOVO no carro do Juras! O azar tá tão grande, que o cara bateu e fugiu!!! O que fazer quando você vai renovar habilitação e não consegue mais enxergar as letras? O futuro é como você imaginava? Esperava carros voadores, viagens especiais e teletransporte? Pois é, muita gente dos anos 80 pensava assim! Você conhece a cidade chamada Cláudio? Com a explosão da bolha dos podcasts, o fim de diversos projetos aconteceu em 2025! Quais os nomes mais famosos do Brasil?==- BLACK FRIDAY! Assine o 99Vidas Bônus por 99 CENTAVOS!!! https://99vidas.com.br/bonus/==- ALURA | Chegou a Black November!!! Durante todo o mês, você terá oportunidades únicas para transformar a sua carreira tech com até 50% de desconto na ALURA!! https://alura.com.br/99vidas

Mesmo já rebaixado e sem chances de reação no Brasileirão, o Sport chegou a abrir 2 a 0 no primeiro tempo, com gols de Léo Pereira e Rafael Thyere, mas não conseguiu segurar o resultado. A equipe levou a virada nos acréscimos e perdeu por 3 a 2 para o Botafogo no Nilton Santos. Celso […]

One-Year Results of the SELUTION DeNovo Tria

Pense de Novo: O Poder de Saber o que Você Não Sabe" - Audiolivro Resumo

Seja apoiador do X do ControleCompre seus jogos na Nuuvem! MARCAÇÕES DE TEMPO(00:00:00) - Introdução(00:06:52) - GTA VI é adiado; Rockstar supostamente combate formação de sindicato(00:27:25) - Muito conteúdo novo em Fortnite(00:37:34) - Nintendo: Switch 2 bate 10 milhões(00:52:20) - Nomes dos videogames viram comuns no Brasil(01:02:39) - Rapidinhas(01:04:52) - EncerramentoCRÉDITOSApresentação: Bruna Penilhas e Guilherme DiasRoteiro: Guilherme DiasEdição: Lucas FunchalThumbnail: Lucas G. FerreiraSiga o XdC: YouTube⁠⁠⁠| Instagram | Bluesky | Threads | ⁠⁠⁠Tik Tok⁠⁠⁠⁠⁠⁠Nossas plataformas e redes⁠⁠⁠Contato: contato@xdocontrole.comContato para anunciantes e parcerias: comercialxdc@gmail.com

Mais de 2,4 milhões de pessoas foram afetadas em oito regiões; são pelo menos 150 mortos e dezenas de desaparecidos. O governo acelera ações de resposta e prepara-se para o possível impacto do supertufão Fung-Wong.

Depois de classificação épica contra a LDU, Palmeiras vai decidir a Libertadores contra o Flamengo, reeditando a final de 2021. Falamos sobre as duas classificações e como os times chegarão para esta decisão.No mais, passamos também pela definição da final da Sul-Americana, que terá o Atlético Mineiro contra o Lanús, além dos destaques do meio de semana nas principais ligas europeias.INSCREVA-SE NA NEWSLETTER! Toda sexta-feira aberta a todos inscritos com nossos textos sobre o que rolou na semana e às terças com conteúdo exclusivo apenas para assinantes: https://newsletter.meiocampo.net/SEJA MEMBRO! Seu apoio é fundamental para que o Meiocampo continue existindo e possa fazer mais. Seja membro aqui pelo Youtube! Se você ouve via podcast, clique no link na descrição para ser membro: https://www.youtube.com/channel/UCSKkF7ziXfmfjMxe9uhVyHw/joinConheça o canal do Bruno Bonsanti sobre Football Manager: https://www.youtube.com/@BonsaFMConheça o canal do Felipe Lobo sobre games: https://www.youtube.com/@Proxima_FaseConheça o canal do Leandro Iamin sobre a Seleção Brasileira: https://www.youtube.com/@SarriaBrasil

US Government Shutdown – What the FDA Can Still Be Doing? When the U.S. government experiences a shutdown, the consequences ripple across every industry — but for medical device manufacturers, the uncertainty can be alarming. In this article, Regulatory Expert Rob Packard explores what happens to the U.S. Food and Drug Administration (FDA) during a shutdown, and how it affects global manufacturers. You'll learn: Which FDA activities continue, and which are suspended How submissions like 510(k), PMA, and De Novo are impacted What happens to clinical trials, recalls, and ongoing investigations Whether this situation has happened before and how long it could last How companies can prepare and what contingency actions to take

Real-World Evidence (RWE) is transforming how regulators evaluate medical devices — but many manufacturers still struggle to use it correctly. In this episode, we break down what RWE really means, how it differs between the FDA and the EU MDR, and how you can design a compliant, global strategy that turns data into regulatory strength. You'll learn: What qualifies as Real-World Data (RWD) and Real-World Evidence (RWE) How the FDA integrates RWE into premarket submissions (510(k), De Novo, PMA) How EU MDR uses RWE through PMCF and PMS The key differences in approach between the two regions A practical 5-step roadmap to build a compliant RWE strategy Common pitfalls (bias, poor traceability, privacy issues) — and how to avoid them

Manchester United vence o clássico contra o Liverpool: será que agora vai? 00:00 - Abertura 01:00 - A ausência e a mensagem do João 04:00 - Os destaques da rodada 05:00 - Man United: estamos iludidos?  06:50 - Escalação e melhores do Man United 09:00 - Já pediram desculpa pro Maguire?  10:00 - Os tabus quebrados pelo United 11:30 - Os problemas do Liverpool 19:55 - Como seria o mundo com o Klopp no United? 21:25 - Entrevista Matheus Cunha 24:50 - Casemiro neles 26:30 - A demissão de Ange Postecoglou  33:40 - Mais uma vitória do Chelsea! 39:00 - A liga dos treinadores 41:00 - Palace x Bournemouth, o jogo da rodada 48:00 - Guuuuuuuners! 56:40 - Entrevista Declan Rice 58:50 - City e Haaland 01:03:50 - Haaland, Kane ou Mbappe? 01:06:10 - Tottenham…  01:11:10 - Outros jogos da rodada Learn more about your ad choices. Visit podcastchoices.com/adchoices

Edgard Maciel de Sá, Cauê Rademaker, Phill e Giba Perez analisam a atuação contra o Mirassol, a anulação do gol de Acosta, o momento do argentino e a importância da Data Fifa para o trabalho de Zubeldia. DÁ O PLAY!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

人工智慧（AI）如何改變藥物開發？藥物開發從臨床前研究到臨床試驗，通常需要超過十年時間和數十億美元的投資，卻仍有高達九成的藥物在臨床試驗中失敗。這些挑戰，現在 AI 正在各種方面掀起革命。在這系列節目中，我們將探討 AI 在藥物開發領域中的應用，並介紹在這個快速發展的領域中工作的專家。 本集為《AI 藥物開發系列》的第三集。我們邀請到加州大學聖塔克魯茲分校的葉先偉教授。他曾在諾貝爾獎得主 David Baker 的實驗室進行博士後研究。本集主題將探討 AI 蛋白質設計，介紹他如何設計新型 luciferase 與生物感測器 biosensor，並講解 2024 年諾貝爾獎的研究，以及他對於 AI 蛋白質設計未來發展的看法。  

Faça sua assinatura! www.resumido.cc/assinatura--China ultrapassa o mundo em número de robôs, carpinteiros são contratados para serem filmados para treinamento de IA e pessoas vendem as próprias ligações também para isso. O ChatGPT quer tomar conta do seu dia, startups criam cópias de arte tão perfeitas que abrem um novo mercado. Pelo menos o Instagram promete nos dar algum controle do algoritmo.Qual o preço das nossas experiências?No RESUMIDO #332: China lidera corrida global dos robôs, carpinteiros viram espetáculo ao vivo, plataforma paga por ligações telefônicas para treinar IA, Geração Z tenta blindar carreira contra substituição tecnológica, Instagram atinge três bilhões de usuários promete controle sobre algoritmo e muito mais!--Ouça e confira todos os links comentados no episódio: https://resumido.cc/podcasts/robos-chegaram-falsas-promessas-da-ia-controle-seu-feed